Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,199.0
25.2 (0.79%)

 

  • STI Straits Times Index
    3,199.0
    25.2 (0.79%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,606.0
    7.7 (0.48%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,787.2
    377.5 (1.49%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,593.2
    25.0 (0.70%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,215.5
    190.1 (0.65%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,656.0
    -2.8 (-0.04%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,613.6M
  • Value: 1,230.2M
  • Rise: 192
  • Fall: 154
  • Unch: 405

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.081-0.001
Hatten Land0.073-0.005
Jiutian Chemical0.089-0.002
Shen Yao0.003-0.001
Rex Intl0.350+0.025
AusGroup0.029+0.003
Singtel2.550-
Sinjia Land0.052+0.005
Oceanus0.040-
Leader Env0.083+0.009

World Indices

World Indices
Name Last Change
Nasdaq 15,021.8 +124.5
HSI 25,787.2 +377.5
HSCEI 9,136.1 +164.7
Jakarta 6,656.0 -2.8
Nikkei 225 29,215.5 +190.1
SSE Comp 3,593.2 +25.0
Shanghai A 3,765.7 +26.2
Shanghai B 280.0 +0.7
KOSPI 3,029.0 +22.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Pharmesis Intl PHARMESIS INTERNATIONAL LTD.
Quotes 10 Minutes Delayed. Updated at 19 Oct 2021 09:54
Last (SGD): 0.127 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 0.127
Buy Price 0.148 Sell Price 0.240
Buy Volume ('000) 6.8 Sell Volume ('000) 7.8
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.05126 Trailing EPS (SGD) e -0.02252 NAV (SGD) b 0.5069
PE a - Trailing PE f - Price / NAV b 0.2505
Dividend (SGD) d - Cash In Hand (SGD) g 0.1197 Issued & Paid-up Shares c 23,000,000
Dividend Yield (%) d - Price / Cash In Hand g 1.061 Treasury Shares h -
Beta - 75 Daysi -0.358 R-Squared - 75 Days(%)i 0.18 Market Cap (M) 2.921
Beta - 500 Daysi -0.286 R-Squared - 500 Days (%)i 0.27 Enterprise Value (M) 3.889
Piotroski F Score 4 Exchange Code BFK Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 63.2784 6-Month VWAP 0.153 Free Float (%) -
Under CPF Investment Scheme (CPFIS) Yes
Sector & Industry Manufacturing - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Fledgling Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 14 Apr 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Pharmesis Intl SGX 2.921 - - 0.2505 -
Industry Medical & Biotechnology SGX 1,041.560 19.260 16.446 1.4669 1.877
Pharmaceuticals: Major SGX 88.966 2431.015 115.115 3.6573 0.698
Index FTSE ST Fledgling Index SGX 118.242 142.744 38.737 0.7388 2.364
Local Peer IX Biopharma SGX 175.349 - - 8.1597 -
Local Peer Hyphens Pharma SGX 88.627 14.383 14.304 1.7868 2.102
Global Peer JOHNSON & JOHNSON NYSE 421,512.698 28.647 23.724 6.0580 2.486
Global Peer PFIZER INC NYSE 231,668.431 24.092 17.513 3.3076 3.677
Global Peer ELI LILLY AND COMPANY NYSE 228,603.727 36.909 37.657 35.4733 1.239
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 200,450.143 24.685 22.287 3.7092 2.341
Global Peer MERCK & CO INC NYSE 195,295.196 27.635 35.056 5.8658 3.213
Global Peer ABBVIE INC NYSE 189,848.147 41.670 28.813 15.1044 4.500
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 183,696.428 57.477 48.713 11.7183 1.958
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 183,335.881 28.451 25.753 17.5356 1.301
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 126,526.943 - - 3.4375 3.263
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 121,368.928 8.646 17.526 1.6184 2.784
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), REPLIGEN CORP (NASDAQ), CANSINO BIOLOGICS INC (HKEx), ORGANON & CO (NYSE), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SINOPHARM GROUP CO. LTD. (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CUREVAC NV (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REMEGEN CO LTD (HKEx), ALLAKOS INC (NASDAQ), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), INNOCARE PHARMA LTD (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), NEKTAR THERAPEUTICS (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), ERASCA INC (NASDAQ), ADC THERAPEUTICS SA (NYSE), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), IGM BIOSCIENCES INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), EVEREST MEDICINES LTD (HKEx), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), SSY GROUP LIMITED (HKEx), CSTONE PHARMACEUTICALS (HKEx), OCUMENSION THERAPEUTICS (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), GENERATION BIO CO (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ZYMEWORKS INC (NYSE), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), Kimia Farma Tbk. (IDX), IMMUNOTECH BIOPHARM LTD (HKEx), PROCAPS GROUP S A (NASDAQ), ABBISKO CAYMAN LTD (HKEx), GOSSAMER BIO INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), KRONOS BIO INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ANTENGENE CORP LTD (HKEx), KEROS THERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), GH RESEARCH PLC (NASDAQ), ANNEXON INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PETIQ INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), TRANSCENTA HOLDING LTD (HKEx), ALIGOS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), GRITSTONE BIO INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), HUA MEDICINE (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), Soho Global Health Tbk. (IDX), BOLT BIOTHERAPEUTICS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), AC IMMUNE SA (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), IGBB (Bursa), EVOLUS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CLENE INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), ESSA PHARMA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), 89BIO INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), RACE ONCOLOGY LTD (ASX), VERRICA PHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), EYEPOINT PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), CLEARSIDE BIOMEDICAL INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), CYBIN INC (NYSE American), CITIUS PHARMACEUTICALS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), ATHENEX INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BSTEAD (Bursa), NEXIMMUNE INC (NASDAQ), HARROW HEALTH INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), XOMA CORP (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), DURECT CORP (NASDAQ), PHARMA (Bursa), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VINCERX PHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GAMIDA CELL LTD (NASDAQ), TRICIDA INC (NASDAQ), OBSEVA SA (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), IMMUNIC INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), MUSTANG BIO INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), IP (SET), ONCTERNAL THERAPEUTICS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), EYENOVIA INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), NOVAN INC (NASDAQ), POLYPID LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), NOXOPHARM LTD (ASX), KALA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), Merck Tbk. (IDX), ODONATE THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), KOTRA (Bursa), LANTERN PHARMA INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), LANNETT CO INC (NYSE), IMARA INC (NASDAQ), CRESO PHARMA LTD (ASX), TEMPEST THERAPEUTICS INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), APTORUM GROUP LIMITED (NASDAQ), MEDIWOUND LTD (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), AILERON THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), GALECTO INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MANNATECH INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), ALLENA PHARMACEUTICALS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), PAK FAH YEOW INTERNATIONAL (HKEx), NOVA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), EXOPHARM LTD (ASX), ABVC BIOPHARMA INC (NASDAQ), INVION LTD (ASX), VYNE THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), VIRPAX PHARMA INC (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), RENOVORX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), BAUDAX BIO INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), SEQLL INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), VALLON PHARMACEUTICALS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), VIRIOS THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), PHARMAXIS (ASX), XORTX THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), PALLA PHARMA LTD (ASX), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), JCT (SET), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), NLS PHARMACEUTICS LTD (NASDAQ), SUNZEN (Bursa), HOTH THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), ONCOSIL MEDICAL LIMITED (ASX), TREVI THERAPEUTICS INC (NASDAQ), ACRUX (ASX), IMMURON LIMITED (ASX), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TALI DIGITAL LIMITED (ASX), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), ISLAND PHARMACEUTICALS LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days --0.025
-16.45 %
Medium Term Return 3 Months --0.023
-15.33 %
6 Months --0.088
-40.93 %
1 Year --0.138
-52.08 %
Long Term Return 2 Years --0.038
-23.03 %
3 Years --0.053
-29.44 %
5 Years --0.403
-76.04 %
Annualised Return Annualised --
-24.85 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.127 - 0.450 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High -0.323 % Change From 1 Year High (%) -71.78
2 Years Range 0.117 - 0.625 Change From 2 Years Low +0.010 % Change From 2 Years Low (%) +8.55
Change From 2 Years High -0.498 % Change From 2 Years High (%) -79.68
5 Years Range 0.115 - 0.625 Change From 5 Years Low +0.012 % Change From 5 Years Low (%) +10.43
Change From 5 Years High -0.498 % Change From 5 Years High (%) -79.68
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 29 September 2003 under the name of Sinopharm Pte Ltd and it changed its name to Pharmesis International Pte Ltd on 16 April 2004. It adopted its current name on 30 August 2004.Pharmesis specializes in the manufacture of pharmaceutical products, including western medicine and Traditional Chinese Medicine ('TCM’’).Under its two subsidiaries, Kinna Pharm and Longlife, it specializes in the manufacturing of pharmaceutical products in the form of tablets, granules, pills, etc, including TCM formulated products for the treatment of illnesses relating to the liver and gall bladder. Its two main products are ATT tablets and Gansu granules. Additionally, its business also includes the research and development, production, sale and marketing of pharmaceutical products. These pharmaceutical products are sold in China and they include western medicine products under the '?? ' brand, while its TCM formulated products are sold under the '???? ' brand.Leveraging its research and development capabilities and in-house expertise in pharmaceutical products for the treatment of illnesses relating to the liver and gall bladder, Pharmesis has successfully obtained the license to produce ATT tablets in China. Similarly, it is the only Group with the right to produce Gansu granules from Ganhuangcao in China.With sales and marketing network of approximately 900 sales personnel across China, its products can be found in 2,000 hospitals in many cities within China. The Group's two production facilities are located in Chengdu and Gulin, China.

IPO Performance

Listing Date 06 Oct 2004 Full Subscription Rate (x) 11.45
No of Placement Shares (M) 46.20 No of Public Offer Shares (M) 3.80 Public Offer Subscription Rate (x) 138.48
IPO Price (SGD) a 2.500 First Day Close (SGD) a 3.900 First Week Close (SGD) a 3.700
Current vs IPO Price (%) -94.92 First Day Gain (%) +56.00 First Week Gain (%) +48.00
Notes:
  1. Adjusted for the following: Share Consolidation 1 for 10 on 27/08/2015

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(2.14 MB)
Annual Report 2019 Dec 2019 Part 1(5.25 MB)
Annual Report 2018 Dec 2018 Part 1(6.72 MB)
Annual Report 2017 Dec 2017 Part 1(6.64 MB)
Annual Report 2016 Dec 2016 Part 1(1.05 MB)
Part 2(0.12 MB)
Annual Report 2015 Dec 2015 Part 1(10.35 MB)
Annual Report 2014 Dec 2014 Part 1(1.16 MB)
Annual Report 2013 Dec 2013 Part 1(1.00 MB)
Annual Report 2012 Dec 2012 Part 1(4.42 MB)
Annual Report 2011 Dec 2011 Part 1(0.72 MB)
Annual Report 2010 Dec 2010 Part 1(1.32 MB)
Annual Report 2009 Dec 2009 Part 1(2.02 MB)
Annual Report 2008 Dec 2008 Part 1(1.00 MB)
Annual Report 2007 Dec 2007 Part 1(1.34 MB)
Annual Report 2006 Dec 2006 Part 1(0.03 MB)
Part 2(2.25 MB)
Part 3(0.23 MB)
Annual Report 2005 Dec 2005 Part 1(0.88 MB)
IPO Prospectus
IPO Prospectus 2004 Oct 2004 Part 1(14.34 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
19 Oct 2021 0.127 0.127 0.127 0.127 - -
18 Oct 2021 0.127 0.127 0.127 0.127 - -
15 Oct 2021 0.127 0.127 0.127 0.127 - -
14 Oct 2021 0.127 0.127 0.127 0.127 - -
13 Oct 2021 0.127 0.127 0.127 0.127 - -
12 Oct 2021 0.127 0.127 0.127 0.127 - -
11 Oct 2021 0.127 0.127 0.127 0.127 - -
08 Oct 2021 0.127 0.127 0.127 0.127 - -
07 Oct 2021 0.127 0.127 0.127 0.127 - -
06 Oct 2021 0.127 0.127 0.127 0.127 - -
05 Oct 2021 0.127 0.127 0.127 0.127 500 0.1270
04 Oct 2021 0.152 0.152 0.152 0.152 - -
01 Oct 2021 0.152 0.152 0.152 0.152 - -
30 Sep 2021 0.152 0.152 0.152 0.152 - -
29 Sep 2021 0.152 0.152 0.152 0.152 - -
28 Sep 2021 0.152 0.152 0.152 0.152 - -
27 Sep 2021 0.152 0.152 0.152 0.152 - -
24 Sep 2021 0.152 0.152 0.152 0.152 - -
23 Sep 2021 0.152 0.152 0.152 0.152 - -
22 Sep 2021 0.152 0.152 0.152 0.152 - -
21 Sep 2021 0.152 0.152 0.152 0.152 - -
20 Sep 2021 0.152 0.152 0.152 0.152 10,600 0.1520
Summary
Current 2 Weeks
(06 Oct 2021 to 19 Oct 2021)
0.127 0.127 0.127 0.127 - -
Previous 2 Weeks
(22 Sep 2021 to 05 Oct 2021)
0.152 0.152 0.127 0.127 500 -
4 Weeks from
(25 Aug 2021 to 21 Sep 2021)
0.150 0.150 0.127 0.152 10,600 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.